EGFR and exocrine pancreatic carcinoma: In the present study in human pancreatic carcinoma cell line PANC-1, Δ6D expression was tested for responsiveness to the synthetic PPARδ agonist GW0742, under either MEK/ERK1/2 or epidermal growth factor receptor (EGFR) signaling pathway blockade.